AcelRx Pharmaceuticals, Inc. (ACRX) Insider Lawrence G. Hamel Sells 10,161 Shares of Stock
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) insider Lawrence G. Hamel sold 10,161 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the transaction, the insider now directly owns 16,379 shares in the company, valued at $86,644.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of AcelRx Pharmaceuticals, Inc. (ACRX) opened at 5.50 on Wednesday. The company’s market cap is $249.59 million. AcelRx Pharmaceuticals, Inc. has a 1-year low of $1.95 and a 1-year high of $5.75. The stock has a 50 day moving average price of $3.44 and a 200-day moving average price of $2.88.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.01). The company had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. Analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the business. LMR Partners LLP acquired a new stake in shares of AcelRx Pharmaceuticals during the second quarter worth $319,000. Teachers Advisors LLC boosted its position in shares of AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after acquiring an additional 8,475 shares during the period. WealthTrust Axiom LLC boosted its position in shares of AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after acquiring an additional 70,000 shares during the period. Bank of New York Mellon Corp boosted its position in shares of AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after acquiring an additional 6,942 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in shares of AcelRx Pharmaceuticals in the second quarter valued at about $530,000. Hedge funds and other institutional investors own 23.32% of the company’s stock.
ACRX has been the topic of a number of recent analyst reports. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 1st. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Roth Capital reissued a “buy” rating and set a $12.50 target price on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 10th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.93.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.